Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume 104, Issue 12, Pages 1593-1599
Publisher
Wiley
Online
2013-09-05
DOI
10.1111/cas.12281
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
- (2012) A. Rajan et al. CLINICAL CANCER RESEARCH
- The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers
- (2011) Danny Vesprini et al. CUAJ-Canadian Urological Association Journal
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair
- (2010) D. A. Loser et al. MOLECULAR CANCER THERAPEUTICS
- Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair
- (2010) Eva Petermann et al. MOLECULAR CELL
- Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
- (2009) T. Hay et al. CANCER RESEARCH
- PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
- (2009) Helen E Bryant et al. EMBO JOURNAL
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
- (2008) B. Evers et al. CLINICAL CANCER RESEARCH
- Oesophagectomy after Definitive Chemoradiation in Patients with Locally Advanced Oesophageal Cancer
- (2008) S. Borghesi et al. CLINICAL ONCOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer
- (2008) Thomas D. Penning et al. JOURNAL OF MEDICINAL CHEMISTRY
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started